Marshall Wace’s Outset Medical OM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-170,758
Closed -$634K 3553
2025
Q4
$634K Sell
170,758
-248,360
-59% -$2.13M ﹤0.01% 2145
2025
Q3
$5.92M Sell
419,118
-102,282
-20% -$1.59M 0.01% 1128
2025
Q2
$10M Sell
521,400
-128,864
-20% -$2.01M 0.01% 839
2025
Q1
$7.19M Buy
+650,264
New +$7.75M 0.01% 901
2024
Q4
Sell
-6,602
Closed -$67.3K 2892
2024
Q3
$67.3K Sell
6,602
-14,344
-68% -$427K ﹤0.01% 2405
2024
Q2
$1.21M Buy
20,946
+17,383
+488% +$852K ﹤0.01% 1607
2024
Q1
$119K Buy
3,563
+2,214
+164% +$112K ﹤0.01% 2292
2023
Q4
$109K Buy
+1,349
New +$110K ﹤0.01% 2036
2023
Q2
Sell
-8,090
Closed -$2.23M 2826
2023
Q1
$2.23M Buy
+8,090
New +$2.97M ﹤0.01% 1395
2022
Q4
Sell
-12,552
Closed -$3M 3286
2022
Q3
$3M Buy
12,552
+1,134
+10% +$304K 0.01% 1747
2022
Q2
$2.55M Buy
+11,418
New +$4.91M 0.01% 1818
2022
Q1
Sell
-3,858
Closed -$2.67M 3829
2021
Q4
$2.67M Buy
3,858
+915
+31% +$677K ﹤0.01% 1848
2021
Q3
$2.18M Buy
+2,943
New +$2.01M 0.01% 1477
2021
Q2
Sell
-8,716
Closed -$7.11M 2956
2021
Q1
$7.11M Sell
8,716
-7,657
-47% -$5.91M 0.03% 633
2020
Q4
$14M Buy
+16,373
New +$12.6M 0.08% 263

Other funds holding OM

Marshall Wace's OM Position: Q1 2026 in Review

Marshall Wace sold out of Outset Medical (OM) in Q1 2026, closing a stake of 170,758 shares — an estimated $634K sold.

Marshall Wace first reported a position in OM in Q4 2020 and held it in 15 quarters. The position peaked at $14M in Q4 2020. 99 funds tracked by Wall St. Rank hold OM as of Q1 2026.

  • Marshall Wace reported no remaining Outset Medical position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 170,758 Outset Medical shares in Q1 2026, an estimated $634K.
  • Marshall Wace first reported a position in Outset Medical in Q4 2020 and held it in 15 quarters.
  • Marshall Wace's Outset Medical position peaked at $14M in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Outset Medical as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.